892664-20-9 Usage
Molecular structure
Complex and highly specific The compound has a complex structure with multiple substituents, including chlorine and fluorine atoms, attached to a boron-containing organic framework.
Boron-containing organic compound
Unique properties The presence of boron in the compound imparts unique properties and reactivity, making it distinct from other organic compounds.
Chlorine and fluorine substituents
Enhanced reactivity The presence of multiple chlorine and fluorine atoms in the compound can increase its reactivity and make it more suitable for various chemical reactions and processes.
Potential applications
Pharmaceuticals, agrochemicals, and materials science Due to its unique properties and reactivity, 2-(5-chloro-2-{[4-chloro-2-fluorophenylmethyl]oxy}phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane has potential applications in various fields, including the development of new drugs, agrochemicals, and advanced materials.
Research and development tool
Valuable for R&D The compound's complex structure and specific properties make it a valuable tool for research and development in the mentioned fields.
Safety and environmental considerations
Careful handling and storage required As a boron-containing compound, it is essential to handle and store 2-(5-chloro-2-{[4-chloro-2-fluorophenylmethyl]oxy}phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane carefully to minimize potential risks to human health and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 892664-20-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,9,2,6,6 and 4 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 892664-20:
(8*8)+(7*9)+(6*2)+(5*6)+(4*6)+(3*4)+(2*2)+(1*0)=209
209 % 10 = 9
So 892664-20-9 is a valid CAS Registry Number.
892664-20-9Relevant academic research and scientific papers
Selection and development of the manufacturing route for EP1 antagonist GSK269984B
Whiting, Matthew,Harwood, Kathy,Hossner, Frank,Turner, Peter G.,Wilkinson, Mark C.
, p. 820 - 831 (2011/03/19)
A potential manufacturing route for the EP1 antagonist GSK269984B was developed. Four synthetic approaches were examined, and a successful realisation of each is presented. The rationale supporting selection of the preferred route is discussed.
Mild and selective synthesis of an aryl boronic ester by equilibration of mixtures of boronic and borinic acid derivatives
Hawkins, Vanessa F.,Wilkinson, Mark C.,Whiting, Matthew
, p. 1265 - 1268 (2013/01/03)
Quenching of aryl Grignard reagents with 2-isopropoxy-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane (isopropyl pinacol borate) under noncryogenic conditions can lead to mixtures of the corresponding boronic ester along with, generally undesired, borinic acid derivatives. We have found that in certain cases gentle heating of the crude reaction mixtures leads to complete equilibration to give the borinic esters as the sole product which can then be isolated in high yield. This novel equilibration can reduce the need for use of cryogenic conditions or large excesses of reagents to obtain selectivity during boronic ester syntheses.
PYRIDYL COMPOUNDS
-
Page/Page column 22-23, (2008/06/13)
Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein R1, R2, and R3 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions compris
PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES
-
Page/Page column 43, (2008/06/13)
Compounds of formula (I) or a pharmaceutiically acceptable derivative thereof: wherein X, Y, Z, R2a, R2b, R3a, R3b, R8, R9, and Rx are as defined in the specification, a process
